Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

Stopped early · Phase 4

Conditions studied: Proteinuria, Transplant Glomerulopathy

In brief

The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.

Key facts

Study ID

NCT02057523

Run by

University of Illinois at Chicago

People needed

2

Starts

2014-09-01

Expected to finish

2015-09-01

Last updated by the study team

2020-09-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Kidney transplant recipients with confirmed transplant glomerulopathy on kidney biopsy.
• Failed standard therapy (>25% reduction in proteinuria) including maximum use of an ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than 130/80 and optimization of their immunosuppression

You may not qualify if…

• Diabetes

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.